Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (HKG:1349)
Hong Kong
· Delayed Price · Currency is HKD 3.060
+0.030 (0.99%)
Mar 10, 2026, 3:59 PM HKT
HKG:1349 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 685.8 | 709.4 | 850.73 | 1,031 | 1,140 | Upgrade
|
| Other Revenue | - | - | - | - | 0.5 | Upgrade
|
| Revenue | 685.8 | 709.4 | 850.73 | 1,031 | 1,140 | Upgrade
|
| Revenue Growth (YoY) | -3.33% | -16.61% | -17.50% | -9.57% | 36.76% | Upgrade
|
| Cost of Revenue | - | 63.46 | 74.08 | 86.29 | 81.02 | Upgrade
|
| Gross Profit | 685.8 | 645.95 | 776.66 | 944.87 | 1,059 | Upgrade
|
| Selling, General & Admin | - | 341.04 | 426.45 | 599.5 | 660.26 | Upgrade
|
| Research & Development | - | 314.16 | 243.76 | 226.85 | 224.39 | Upgrade
|
| Other Operating Expenses | 841.2 | 7.44 | 5.39 | 6.84 | 6.15 | Upgrade
|
| Operating Expenses | 841.2 | 653.7 | 699.5 | 830.78 | 896.57 | Upgrade
|
| Operating Income | -155.4 | -7.75 | 77.15 | 114.09 | 162.72 | Upgrade
|
| Interest Expense | - | -0.59 | -3.07 | -1.54 | -1.06 | Upgrade
|
| Interest & Investment Income | - | 5.55 | 7.97 | 11.29 | 25.89 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.15 | -1.08 | -0.83 | 0.14 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.45 | -0.05 | -0.42 | -0.14 | 6.21 | Upgrade
|
| EBT Excluding Unusual Items | -155.85 | -2.69 | 80.56 | 122.88 | 193.91 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -10.41 | -4.35 | -1.28 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.03 | 0.3 | 1.92 | 1.78 | Upgrade
|
| Asset Writedown | - | -3.93 | -5 | -1.83 | -2.15 | Upgrade
|
| Other Unusual Items | - | 22.46 | 26.02 | 10.61 | 22.38 | Upgrade
|
| Pretax Income | -155.85 | 5.46 | 97.53 | 132.29 | 215.92 | Upgrade
|
| Income Tax Expense | 1.59 | -33.98 | -10.92 | -4.98 | 3.54 | Upgrade
|
| Earnings From Continuing Operations | -157.44 | 39.43 | 108.45 | 137.27 | 212.38 | Upgrade
|
| Minority Interest in Earnings | - | 0.3 | 0.18 | 0.72 | 0.92 | Upgrade
|
| Net Income | -157.44 | 39.73 | 108.63 | 138 | 213.3 | Upgrade
|
| Net Income to Common | -157.44 | 39.73 | 108.63 | 138 | 213.3 | Upgrade
|
| Net Income Growth | - | -63.42% | -21.28% | -35.30% | 29.54% | Upgrade
|
| Shares Outstanding (Basic) | 1,050 | 1,037 | 1,034 | 1,030 | 1,041 | Upgrade
|
| Shares Outstanding (Diluted) | 1,050 | 1,037 | 1,034 | 1,031 | 1,045 | Upgrade
|
| Shares Change (YoY) | 1.26% | 0.23% | 0.29% | -1.29% | 5.59% | Upgrade
|
| EPS (Basic) | -0.15 | 0.04 | 0.11 | 0.13 | 0.20 | Upgrade
|
| EPS (Diluted) | -0.15 | 0.04 | 0.11 | 0.13 | 0.20 | Upgrade
|
| EPS Growth | - | -63.51% | -19.19% | -35.00% | 20.17% | Upgrade
|
| Free Cash Flow | - | -59.18 | -27.95 | 77.96 | 148.78 | Upgrade
|
| Free Cash Flow Per Share | - | -0.06 | -0.03 | 0.08 | 0.14 | Upgrade
|
| Dividend Per Share | - | 0.050 | 0.070 | 0.070 | 0.070 | Upgrade
|
| Dividend Growth | - | -28.57% | - | - | 40.00% | Upgrade
|
| Gross Margin | 100.00% | 91.05% | 91.29% | 91.63% | 92.90% | Upgrade
|
| Operating Margin | -22.66% | -1.09% | 9.07% | 11.06% | 14.27% | Upgrade
|
| Profit Margin | -22.96% | 5.60% | 12.77% | 13.38% | 18.70% | Upgrade
|
| Free Cash Flow Margin | - | -8.34% | -3.29% | 7.56% | 13.05% | Upgrade
|
| EBITDA | -101.91 | 45.74 | 129.05 | 186.92 | 216.5 | Upgrade
|
| EBITDA Margin | -14.86% | 6.45% | 15.17% | 18.13% | 18.99% | Upgrade
|
| D&A For EBITDA | 53.49 | 53.49 | 51.89 | 72.83 | 53.78 | Upgrade
|
| EBIT | -155.4 | -7.75 | 77.15 | 114.09 | 162.72 | Upgrade
|
| EBIT Margin | -22.66% | -1.09% | 9.07% | 11.06% | 14.27% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 1.64% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.